Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like BIOTRONIK Release: New ICD Lead With Helical Design Now Launched In Europe April 5, 2017 PROMETHERA Biosciences S.A./N.V. Announces Key Additions To Its Executive Management Team February 8, 2017 Eli Lilly Shakes Up Cancer R&D Strategy, Seeks New Home for Seven Pipeline Drugs July 24, 2017
PROMETHERA Biosciences S.A./N.V. Announces Key Additions To Its Executive Management Team February 8, 2017
